Cyanidin, a key flavonoid that is present in red berries and other fruits, attenuates the development of several diseases, including asthma, diabetes, atherosclerosis, and cancer, through its anti-inflammatory effects. We investigated the molecular basis of cyanidin action. Through a structure-based search for small molecules that inhibit signaling by the proinflammatory cytokine interleukin-17A (IL-17A), we found that cyanidin specifically recognizes an IL-17A binding site in the IL-17A receptor subunit (IL-17RA) and inhibits the IL-17A/IL-17RA interaction. Experiments with mice demonstrated that cyanidin inhibited IL-17A-induced skin hyperplasia, attenuated inflammation induced by IL-17-producing T helper 17 (T H 17) cells (but not that induced by T H 1 or T H 2 cells), and alleviated airway hyperreactivity in models of steroid-resistant and severe asthma. Our findings uncover a previously uncharacterized molecular mechanism of action of cyanidin, which may inform its further development into an effective small-molecule drug for the treatment of IL-17A-dependent inflammatory diseases and cancer.
INTRODUCTION

Interleukin-17A (IL-17A) is a signature cytokine of T helper 17 (T H 17) cells, a CD4
+ T cell subset that regulates tissue inflammatory responses (1) . Tremendous effort has been devoted to understand the function of IL-17A, demonstrating that this proinflammatory cytokine plays a critical role in the pathogenesis of autoimmune diseases, metabolic disorders, and cancer (2) (3) (4) (5) . IL-17A signals through the IL-17 receptor (IL-17R) complex that consists of the IL-17RA and IL-17RC subunits to transmit signals into cells (6) . The main function of IL-17A is to coordinate local tissue inflammation through increasing the amounts of proinflammatory and neutrophil-mobilizing cytokines and chemokines that are produced. Deficiency in IL-17A signaling components attenuates the pathogenesis of several autoimmune inflammatory diseases, including asthma, psoriasis, rheumatoid arthritis, experimental autoimmune encephalomyelitis (EAE), and tumorigenesis in animal models (2, 3, 5, (7) (8) (9) (10) (11) (12) (13) . High amounts of IL-17A are found in bronchial biopsies and serum obtained from patients with severe asthma, synovial fluids from arthritis patients, serum and brain tissue of multiple sclerosis patients, skin lesions of psoriasis patients, and the serum and tumor tissues of cancer patients (14) (15) (16) (17) . Targeting the binding of IL-17A to IL-17RA is reported to be an effective strategy for treating IL-17A-mediated autoimmune inflammatory diseases (1, 18) . An anti-IL-17A antibody (Cosentyx, also known as secukinumab) was approved by the U.S. Food and Drug Administration (FDA) for the treatment of psoriasis, and it is currently being used in 50 clinical trials for various autoimmune diseases (18) (19) (20) (21) (22) (23) (24) (25) .
Much effort has been devoted to develop more cost-effective alternative therapies, such as small-molecule drugs, to inhibit IL-17A. Natural products and their derivatives play a substantial role in the small-molecule drug discovery and development process (26) . For example, aspirin, one of the oldest and most widely used drugs, was derived from the herbs meadowsweet and willow bark; Mevacor (lovastatin), a well-known cholesterol-lowering drug that acts as an HMG-CoA (3-hydroxy-3-methylglutaryl coenzyme A) reductase inhibitor, was originally isolated from a strain of Aspergillus terreus. Furthermore, many natural products serve as prototypes for synthetic drug development. The invention of the drug Lipitor (atorvastatin), the best-selling small-molecule drug in the world, was built on the discovery of the fungal metabolite-derived inhibitors mevastatin, lovastatin, pravastatin, and simvastatin. The rate of new chemical entity approvals demonstrates that the natural product field is involved in about 40% of all small molecules discovered in the past 15 years.
Here, we identified a potent small-molecule compound, A18 (a natural product also called cyanidin), as an IL-17A inhibitor through computeraided, docking-based virtual screening. Cyanidin is a key pigment present in red berries and other fruits, which has been implicated in attenuating the development of several major diseases, including asthma, diabetes, atherosclerosis, and cancer, by stimulating anti-inflammatory effects through as yet unknown mechanisms. Through biochemical and mutagenesis studies, we showed that A18 specifically bound to a region in the extracellular domain of IL-17RA that overlaps with the binding site for IL-17A and that this binding potently disrupted formation of the IL-17A/IL-17RA complex. We demonstrated that A18 effectively inhibited IL-17A-dependent skin hyperplasia and neutrophilia; attenuated T H 17 cell-induced, but not T H 1 cell-or T H 2 cell-induced, inflammation; and alleviated airway hyperreactivity (AHR) in mouse models of steroid-resistant and severe asthma. These results uncover a previously uncharacterized molecular basis for the cyanidin-mediated reduction of inflammation by specifically inhibiting the IL-17A/IL-17RA pathway. The findings suggest that A18 may be used as a prototype for the development of small-molecule drugs to treat IL-17A-mediated inflammatory diseases and cancer.
RESULTS
The small-molecule A18 specifically inhibits the binding of IL-17A to IL-17RA The crystal structure of the extracellular domain of human IL-17RA complexed with an IL-17A homodimer has been solved (27) . IL-17RA, which is composed of two fibronectin type III domains (D1 and D2) (Fig. 1A) , forms an extensive binding interface with IL-17A, which contains three major interaction sites (27) . In particular, the amino acid residues of IL-17RA that interact with the segment of IL-17A consisting of residues 35 to 46 form a deep binding pocket, which is optimal for drug targeting (Fig. 1A) (Fig. 1C) , which are mutually exclusive with the IL-17RA residues that interact with IL-17A (Fig. 1D) .
The Chemical Abstracts Service (CAS) name of A18 is 2-(3,4-dihydroxyphenyl)-3,5,7-trihydroxy-1-benzopyrylium chloride. The core of A18 (also called cyanidin, a particular form of anthocyanidins in the flavonoid superfamily) has the typical C6-C3-C6 flavonoid skeleton, which contains one heterocyclic benzopyran ring (known as the C ring), one fused aromatic ring (the A ring), and one phenyl constituent (the B ring) (Fig. 1B) . In the cationic form, anthocyanidins have two double bonds in the C ring and hence carry a positive charge. To test the ability of A18 to disrupt IL-17A/IL-17RA binding, we coated purified IL-17A, IL-17E, and IL-17C onto 96-well plates, which was followed by the addition of IL-17RA-Fc, IL-17RB-Fc, and IL-17RE-Fc, respectively, together with serial dilutions of A18. Those receptors that bound to the ligands were detected with a horseradish peroxidase (HRP)-conjugated anti-Fc antibody. A18 showed inhibition efficacy for IL-17A/IL-17RA binding with a median inhibitory concentration (IC 50 ) of 1.68 mM (Fig. 1E ), but it did not efficiently disrupt IL-17E/ IL-17RB or IL-17C/IL-17RE binding (Fig. 1, F and G) .
Consistent with the competition assays, our docking studies showed that A18 and IL-17A shared overlapping binding sites on IL-17RA (Fig. 1, C and D) . The sequences of human and mouse IL-17RA are highly conserved ( fig. S1A ). Among the amino acid residues of IL-17RA that make contact with both chains A and B of IL-17, Asp 262 is a key residue located in the docking pocket of IL-17RA ( fig. S1, A and B S1C ). The same D262A mutation also reduced the binding affinity of IL-17RA for IL-17A (K d was changed from 0.37 mM for the wildtype (WT) receptor to 1.57 mM for the D262A mutant) ( fig. S1D ). In an independent experiment using surface plasmon resonance (SPR), we confirmed the binding of A18 to IL-17RA ( fig. S1E ). These biochemical data suggest that A18 and IL-17A share the same binding site in IL-17RA, which provides the basis for how A18 inhibits the IL-17A/IL-17RA interaction.
A18 specifically inhibits IL-17A-induced gene expression in human and mouse cells Because A18 blocked the IL-17A/IL-17RA interaction in biochemical assays with purified proteins, we further investigated whether A18 was capable of inhibiting the binding of IL-17A to IL-17RA on live cells. We incubated human embryonic kidney (HEK) 293 cells expressing IL-17RA (IL-17RA-239) and HeLa cells (which have endogenous receptors for IL-17A) with biotinylated IL-17A in the presence of phosphate-buffered saline (PBS; negative control), A18, or anti-human IL-17A antibody (positive control), followed by incubation with avidinfluorescein and analysis by flow cytometry. The results showed that A18 inhibited the binding of IL-17A to either ectopically expressed or endogenous IL-17RA ( Fig. 2A) . The amino acid residues in the docking pocket are conserved between human and mouse receptors (Fig. 2B) . We next examined whether A18 exhibited an inhibitory effect on IL-17A activity in cultured human and mouse cells. We found that A18 substantially inhibited the IL-17A-stimulated production of multiple cytokines and chemokines [including CXCL1 (also known as GROa), IL-6, and IL-8 in human cells and CXCL1 (also known as KC), IL-6, and CXCL2 (also known as MIP-2) in mouse cells], whereas A18 showed limited inhibitory activity against the IL-17E-stimulated production of CXCL1 only at the highest concentration (Fig. 2, C to J, and fig. S2 , A to D). IL-17A-mediated signaling events, including the recruitment of the adaptor protein Act1 to IL-17RA and the phosphorylation of inhibitor of nuclear factor kB a (IkBa) and of the mitogen-activated protein kinases (MAPKs) c-Jun N-terminal kinase (JNK), p38, and extracellular signal-regulated kinases 1 and 2 (ERK1/2), were also decreased in the presence of A18 (Fig. 2, K and L) .
Analysis of the crystal structure of IL-17RA showed that IL-17F, similar to IL-17A, also interacted with IL-17RA through the docking pocket discussed earlier (28) . We found that A18 also inhibited the IL-17F-and IL-17A/IL-17F-stimulated expression of target genes in cultured cells ( fig. S2, E and F) . In contrast, A18 had little effect on the IL-17E-induced expression of target genes in the IL-17E-responsive cells HT29 and IL-17RB-expressing mouse embryonic fibroblasts (MEFs) (Fig. 2, F and J) . These data suggest that A18 does not stimulate receptor internalization because IL-17E also uses IL-17RA to transduce signals. In the case of gene expression induced by other cytokines, such as IL-1 and tumor necrosis factor, A18 showed inhibitory activity only at very high concentrations (>100 mM) ( fig. S2, G and H) . These results suggest that A18 specifically blocks IL-17A activity in cultured cells in a dose-dependent manner.
A18 inhibits IL-17A-dependent skin hyperplasia in mice Secukinumab [an anti-IL-17A monoclonal antibody (mAb)] was approved by the FDA for the treatment of psoriasis (18, 21, 25) . Abnormal keratinocyte proliferation is an important hallmark of the pathogenesis of psoriasis, which is a well-defined IL-17A-dependent disease. To examine the effect of A18 on IL-17A-induced epidermal cell proliferation, we intradermally injected the ears of female WT C57BL/6 mice with PBS or with IL-17A alone or together with A18 for six consecutive days. After the injections, the mice treated with IL-17 alone exhibited IL-17A-dependent epidermal hyperplasia, whereas the mice treated with both IL-17 and A18 exhibited reduced hyperplasia (Fig. 3A) . Real-time polymerase chain reaction (RT-PCR) analysis revealed that the abundances of Myc, Cxcl1, and Steap4 mRNAs in the ears of IL-17A-treated mice were increased compared to those in the ears of PBS-treated mice but were not substantially increased in the ears of mice treated with both IL-17 and A18 (Fig.  3B ). We and others previously showed that IL-17A signaling is also required for skin hyperplasia induced by 12-O-tetradecanoylphorbol 13-acetate (TPA) (2) . Here, we found that the TPA-induced epidermal thickness and expression of target genes were substantially reduced by A18 (Fig. 3 , C and D). Together, these data suggest that IL-17A induces epidermal hyperplasia, which was inhibited by A18.
A18 inhibits T H 17 cell-induced, but not T H 1 cell-or T H 2 cell-induced, inflammation in mice
A study showed that IL-17A-producing T H 17 cells play a critical role in the development and pathogenesis of EAE, a mouse model of multiple sclerosis (14) . EAE is markedly suppressed in mice lacking IL-17A or the IL-17RA and IL-17RC subunits. Therefore, T H 17 cell-mediated EAE is a suitable animal disease model in which to test the efficacy and specificity of A18 on IL-17A bioactivity. We found that A18 substantially delayed the onset of EAE and attenuated disease severity in mice that received myelin oligodendrocyte glycoprotein (MOG)-specific T H 17 cells (fig. S3A ); A18-treated mice exhibited diminished demyelination in the spinal cords and reduced expression of IL-17A target genes ( fig. S3 , B and C). However, A18 had no effect on the infiltration into the brains of CD4 + T cells, CD8 + T cells, or F4/ 80 + macrophages, whereas the recruitment of Ly6G + neutrophils into the brains was substantially reduced in the A18-treated mice ( fig. S3D ). These results suggest that A18 suppresses T H 17 cell-mediated EAE, which may partly be a result of attenuation of the IL-17A-dependent recruitment of neutrophils into the central nerve system (CNS). A18 failed to block T H 1 cell-induced EAE in mice ( fig. S3E ), which suggests that the effect of A18 on inflammation in the CNS is specific to T H 17 cell-mediated disease. CD4
+ regulatory T (T reg ) cells accumulate in the CNS during EAE development, reaching their greatest numbers during the recovery phase (29) . The accumulation of these cells in the CNS may limit EAE severity by suppressing the proliferation of effector T cells. We found that A18 did not affect the (K) HeLa cells were transfected with plasmid encoding FLAGtagged WT IL-17RA. Forty-eight hours later, the cells were pretreated with DMSO or 10 mM A18 before being incubated for the indicated times with IL-17A. Top: Whole-cell lysates (WCLs) were subjected to immunoprecipitation (IP) with an anti-FLAG antibody (M2) and then were analyzed by Western blotting with anti-Act1 and anti-FLAG antibodies. Western blots are representative of three independent experiments. Bottom: The relative densities of the bands corresponding to Act1 in the immunoprecipitated samples were normalized to those in the WCLs. Data are means ± SEM of three independent experiments. (L) HeLa cells were pretreated for 1 hour with DMSO or 10 mM A18 before they were treated for the indicated times with IL-17A. The cells were then analyzed by Western blotting with antibodies against the indicated proteins. Top: Western blots are representative of three independent experiments. Bottom: The relative densities of the bands corresponding to pIkBa, pJNK, pp38, and pERK1/ 2 were normalized to that of actin. Data are means ± SEM of three independent experiments. hSMC, human smooth muscle cell; mSMC, mouse smooth muscle cell; mKEC, mouse kidney epithelial cell. AU, arbitrary units. *P < 0.05 when comparing DMSO-treated cells with A18-treated cells. + T reg cells in lymphoid organs (spleen and lymph nodes) or in the CNS during the recovery phase (day 20) (fig. S3F ), suggesting that A18 did not act through T reg cells to alleviate EAE. To determine whether A18 treatment needed to be maintained during EAE, we examined EAE development after the cessation of treatment with A18 (on day 15 when the untreated group of mice exhibited maximal disease severity) ( fig. S3G ). Whereas the clinical score of the mice steadily increased after the withdrawal of A18, disease severity (in both the peak and remission stages) was substantially reduced as compared with that in mice that were never treated with A18. These data suggest that the administration of A18 only during the early stage has beneficial effects on overall disease development, although continuous administration of A18 is required to effectively suppress T H 17 cell-mediated EAE.
To test the efficacy and specificity of A18 on T H 17 cell-versus T H 2 cell-mediated inflammation, we performed experiments in which we adoptively transferred T H 17 or T H 2 cells specific for an ovalbumin-derived peptide (OVA-specific cells), which elicit neutrophilic and eosinophilic airway inflammation, respectively, to recipient mice (Fig. 4A) . We found that A18 substantially reduced T H 17 cell-induced neutrophilia (Fig. 4 , B and C) and inflammatory gene expression in the lungs (Fig. 4D) . Conversely, A18 had no effect on T H 2 cell-induced eosinophilia (Fig. 4E ) or on the expression of genes encoding T H 2 cell-type cytokines in the lungs (Fig. 4F) . Consistent with these findings, A18 substantially inhibited IL-17A-induced pulmonary neutrophilia and the expression of IL-17A target genes (Cxcl1, Il6, and Ccl11) (Fig. 4 , G and H), whereas A18 did not inhibit IL-17E-induced pulmonary eosinophilia or T H 2 cellassociated gene expression (Fig. 4I) . These results suggest that A18 specifically inhibits airway inflammation induced by T H 17 cells but not that induced by T H 2 cells.
A18 attenuates airway inflammation in mouse models of steroid-resistant and severe asthma Previous studies showed that obesity is a major risk factor for the development of asthma and contributes to disease severity (30) (31) (32) (33) . Obese individuals with asthma respond poorly to typical asthma medications, including corticosteroids (33) . A study found that IL-17A signaling provides a critical link between obesity and asthma (34) . Mice fed a high-fat diet (HFD) develop AHR that is IL-17A-dependent. These data suggest that the IL-17A pathway is an important target for the treatment of steroid-resistant, obesityassociated asthma. In our experiments, we found HFD-induced T H 17 cells in the periphery, as well as in the lung, whereas HFD-induced AHR was substantially reduced in IL-17RC −/− mice compared to in WT mice ( fig. S4 , A to C). Because HFD-induced AHR is an IL-17A-mediated disease model, we investigated whether A18 could attenuate disease. Male WT C57BL/6 mice were fed a chow diet (CD) or a HFD for 14 weeks starting at 4 weeks of age and were then treated with or without A18 for the last 4 weeks of the experiment (Fig. 5A ). A18 substantially attenuated HFDinduced AHR and the extent of inflammatory gene expression (Fig. 5 , B and C), which is suggestive of a potential therapeutic role for A18 in the treatment of IL-17A-dependent asthma, including obesity-associated, steroid-resistant asthma.
House dust mite (HDM), a natural allergen to which asthmatics are often sensitized, induces neutrophilic airway inflammation, which is often associated with severe asthma (35) . Consistent with these findings, (C) Eight-week-old female C57BL/6J mice (n = 6 mice per group) were treated on the dorsal skin with PBS, TPA alone, or both TPA and A18. TPA was applied to the mice on days 1 and 4, whereas A18 was applied daily. Left: On day 7, dorsal skin tissue was removed from the mice and subjected to H&E staining to assess epidermal thickness. Images are representative of three independent experiments. Right: Quantitative analysis of epidermal thickness in the indicated groups of mice. (D) Dorsal skin samples from the mice described in (C) were subjected to RT-PCR analysis of the relative abundances of Myc, Cxcl1, and Steap4 mRNAs. Error bars in (C) and (D) represent the SEM calculated from 18 mice from three independent experiments. *P < 0.05. Scale bars, 100 mm.
we showed that IL-17RC −/− mice had substantially reduced neutrophilic airway inflammation in a high-dose HDM-induced model of severe asthma ( fig. S5, A to D) . We then evaluated the ability of A18 to alleviate neutrophilia and AHR in this model of IL-17A-dependent severe asthma (Fig. 5D) . HDM-induced neutrophilia, AHR, and inflammatory gene expression in the lungs were substantially reduced in A18-treated mice compared to those in control mice (Fig. 5, E to H) . Together, the results from both the HFD and HDM experiments suggest that A18 may have a potential therapeutic role in the treatment of IL-17A-mediated steroid-resistant and severe asthma. PBS  TH17  PBS  TH17  PBS  TH17  PBS  TH17  PBS  TH17   PBS  TH2  PBS  TH2  PBS  TH2  PBS  TH2  PBS  TH2   TH2 + A18   PBS   TH17  TH17 + A18 PBS TH2 (E and F) When the mice described in (A) that received the T H 2 cells were sacrificed, the total and indicated immune cell counts in the BAL were quantified (E). In addition, the relative abundances of the indicated mRNAs were determined by RT-PCR analysis (F). (G to I) IL-17A-induced neutrophilic and IL-17E-induced eosinophilic airway inflammation in the 8-week-old BALB/cJ mice (n = 5 mice per treatment group) with or without A18. (G) Representative BAL cytospin preparations from the mice were analyzed. (H and I) The numbers of neutrophils and eosinophils were counted, and the relative abundances of the indicated mRNAs isolated from lung tissue were determined by RT-PCR analysis. Each IL-17A-or IL-17E-based experiment was performed three times with its own PBS control. Data are means ± SEM of three independent experiments. *P < 0.05. Scale bars, 100 mm. i.p., intraperitoneally; i.v., intravenously; i.n., intranasally.
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Certain hydroxyl groups of A18 are critical for its ability to inhibit IL-17A To further develop A18 into a drug candidate, it is important to define the critical elements and functional groups that are responsible for its inhibitory activities. This information will provide guidance for the structural optimization of A18 by medical chemistry in drug development. On the basis of computational docking of A18 to the binding pocket of IL-17RA, all five of the hydroxyl (−OH) groups of A18 are involved in hydrogen bond formation with IL-17RA (Fig. 1C and fig. S6A ). Using existing compounds, we tested the importance of some of the hydroxyl groups in the inhibitory effect of A18. We found that the B3′-OH was critical for the inhibitory activity of A18 in IL-17A/IL-17RA binding assays, because removal or modification of B3′-OH, which generates pelargonidin or peonidin, respectively, substantially increased the IC 50 values of the resulting compounds (>100 mM) ( fig. S6B ). This finding is consistent with our docking model in which B3′-OH makes a potential hydrogen bond with Gln 124 of IL-17RA. We also tested whether removal or modification of the C3-OH, which generates luteolinidin or cyanidin-3-O-glucoside, affected the inhibitory activity of A18 ( fig. S6C ). We found that the IC 50 assay (see Materials and Methods) were noticeably increased (from 1.68 to 6.75 and 6.88 mM, respectively). This suggests that the C3-OH also plays a role in the binding of A18 to IL-17RA, which is consistent with our docking model in which C3-OH makes a potential hydrogen bond with Asp
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, as well as with the finding that the D262A mutation decreased the binding of IL-17RA to A18 (Fig. 1K) . Note that another member of the anthocyanidins A10 (also known as delphinidin), which has an additional hydroxyl group at B5′ as compared with A18, has a comparable GlideScore (which refers to the theoretical or computational binding energy: the smaller the score, the more easily the binding event occurs) and a slightly improved IC 50 value compared to that of A18 ( fig. S6D) . To test the importance of −OH at A5, we synthesized A18D5OH (fig. S6E ). The removal of the hydroxyl group at A5 resulted in a compound that retained some inhibitory activity in the in vitro inhibition assays (IC 50 , >30 mM), but that was much less potent than A18, demonstrating the importance of A5-OH for the activity of A18. Consistent with this finding, the A5-OH group makes a potential hydrogen bond with the backbone of Leu 264 in our docking model. To test the importance of ring C, we synthesized A18-C5 ( fig.  S6F) , in which the six-membered ring C was replaced with a fivemembered ring. A18C5 showed very little activity in an in vitro inhibition assay (IC 50 , >100 mM) ( fig. S6F ). These results suggest that the geometry of ring C in A18 is important for its activity. Together, these data suggest that the scaffold represented by A18 with the regiopresentation of the four hydroxyl groups on rings A and B provides strong hydrogen bonding interactions with the extracellular domain of IL-17RA. These hydroxyl groups (R1 to R4) may be replaced with amines, amides, and cyanides and with other hydrogen bond donor groups to improve the potency of A18 and reduce the metabolism of the hydroxyl groups. Replacement of the R5 groups in the basic skeleton of A18 with certain nonhydroxyl substituents should have minimal effect on the inhibitory activities of the derived compounds. One may replace R5 with F, Cl, or glycoside to improve stability. This basic skeleton of A18 could be used as the prototype for developing A18-derived, small-molecule drug candidates for clinical application ( fig. S6G ).
DISCUSSION
We report the discovery of the small-molecule compound A18 (cyanidin), a member of the anthocyanin subfamily of the flavonoid superfamily, as an effective inhibitor of the binding of IL-17A to IL-17RA, resulting in attenuation of IL-17A signaling and associated diseases. Although monoclonal neutralizing antibodies developed as candidate drugs to target IL-17A or IL-17RA and thus inhibit IL-17A signaling have shown promising results in clinical trials, they have high production costs and limited administration routes (they can be delivered only through intravenous administration). Therefore, our small-molecule, A18-derived drugs could provide cost-effective alternatives for the treatment of IL-17A-dependent inflammatory diseases and cancer.
Cyanidin is a particular type of anthocyanidin (the sugar-free counterparts of anthocyanins), which is present as a pigment in many red berries and other fruits, such as apples and plums, with the highest concentrations found in the skin of the fruit. Cyanidin and its related compounds have various beneficial effects, including antiatherosclerotic, anti-inflammatory, antithrombogenic, antitumor, antiosteoporotic, and antiviral effects in animals and humans (36) (37) (38) (39) (40) . However, the precise mechanism of action of cyanidin is poorly understood. Here, we elucidated a previously uncharacterized molecular mechanism for cyanidin and its related structures based on their ability to inhibit IL-17A/ IL-17RA binding, which is supported by computational modeling, in vitro binding measurements, cell-based assays, and in vivo studies. This inhibitory effect of cyanidin on the IL-17A/IL-17RA interaction helps to explain its anti-inflammatory bioactivities in vivo, because IL-17A is involved in a wide range of chronic inflammatory diseases, including rheumatoid arthritis, multiple sclerosis, EAE, allergeninduced pulmonary inflammation, psoriasis, and cancer. The fact that A18 specifically inhibited inflammation induced by IL-17A from T H 17 cells, but not that induced by T H 1 or T H 2 cells, supports the hypothesis that the inhibitory mechanism of cyanidin is due to its ability to block the binding of IL-17A to IL-17RA. Accumulating evidence suggests that aberrant IL-17A production is a key determinant of severe and steroid-resistant forms of asthma (11, (41) (42) (43) (44) (45) . We found that A18 attenuated airway inflammation and AHR in mouse models of steroid-resistant and severe asthma. Our studies suggest that cyanidinderived small molecules could be developed into a new class of drugs to treat severe asthmatics and patients with other IL-17A-dependent autoimmune diseases and cancer.
MATERIALS AND METHODS
Mice
B6.OT-II T cell receptor (TCR) transgenic mice and WT C57BL/6
or BALB/cJ mice were purchased from the Jackson Laboratories. IL-17RC-deficient mice were obtained from W. Ouyang (Genentech, San Francisco, CA) and were described previously (2). All animal experiments were approved by the Institutional Animal Care and Use Committee of the Cleveland Clinic. were maintained in Dulbecco's modified Eagle's medium supplemented with 10% fetal calf serum, penicillin (100 U/ml), and streptomycin (100 mg/ml). Human primary smooth muscle cells were provided by S. Comair (Department of Pathobiology, Cleveland Clinic). Mouse primary smooth muscle cells and kidney epithelial cells were isolated and cultured as described previously (8, 46) . Lack of Mycoplasma was confirmed for all cell cultures using the Mycoplasma PCR Detection Kit (Sigma, MP0035-1KT). All cell lines were obtained from and authenticated by the American Type Culture Collection.
Reagents and cell culture
Compounds
Cyanidin chloride (A18; CAS 528-58-5), peonidin (CAS 134-01-0), and cyanidin-3-O-glucoside (CAS 7084-24-4) were obtained from Santa Cruz Biotechnology. Pelargonidin (CAS 134-04-3) and delphinidin (CAS 528-53-0) were purchased from Sigma-Aldrich. Luteolinidin (CAS 1154-78-5) was obtained from INDOFINE Chemical Company. A18D5OH and A18-C5 were synthesized by Bellen Chemistry and WuXi AppTec, respectively.
High-throughput virtual screening
Virtual screening was performed with Maestro 9.6 software (Schrödinger Release 2013-3, Schrödinger LLC.) and the high-performance computing (HPC) cluster server at the Case Western Reserve University (CWRU) with the following procedures. In terms of ligand preparation, the compound library for screening, which contains 89,253 compounds in SDF format, was downloaded from the online resources NCI Plated 2007 and NCI Diversity 3 (http://zinc.docking.org/catalogs/ncip). Before docking, all compounds were preprocessed with the LigPrep module in Maestro. Each compound was desalted, and tautomers of the possible ionization states in the pH range of 5.0 to 9.0 were generated by Epik mode in the force field of OPLS_2005. In terms of protein preparation, the structure of IL-17RA was derived from PDB (PDB code 4HSA or 3JVF). Before docking, the protein was processed and refined with the Protein Preparation module in Maestro. In general, hydrogen atoms were added, water molecules were removed, H-bond assignment was optimized, and restrained minimization was conducted with the force field of OPLS_2005. To generate the docking grid, we used the segment (amino acid residues 35 to 46) derived from IL-17A or the segment (residues 36 to 47) from IL-17F, which forms a complex with IL-17RA, to define the center of the docking pocket and set the scaling factor and the partial charge cutoff of the van der Waals radii at 1.0 and 0.25, respectively. This step was performed with the Receptor Grid Generation module in Maestro. In terms of glide docking, initially, all of the prepared compounds were docked into the defined binding pocket of IL-17RA using the high-throughput virtual screening mode and ranked by the docking score. The two sets of the top 2500 compounds (from 4HSA and 3JVF respectively) were then both redocked into IL-17RA separately with the SP (standard precision) and XP (extra precision) modes, respectively. The compounds seen in both sets were selected and compared for their SP and XP docking scores, and their docking conformations were then carefully inspected by visual observation. Eventually, 64 potential compounds were purchased for bioassays. The docking simulations were conducted on the HPC cluster server at CWRU, and the docking conformation analysis was performed with PyMol.
Ligand-receptor binding inhibition assay
For binding assays with purified proteins, we coated ELISA plates with human IL-17A, IL-17E, or IL-17C (each at 2 mg/ml in PBS) to which we added human IL-17RA-Fc, human IL-17RB-Fc, or human IL-17RE-Fc (each at 150 ng/ml), respectively. The plates were then incubated for 1 hour, which was followed by incubation with goat HRP-conjugated anti-human IgG Fc secondary antibody in the presence or absence of A18 for 1 hour. ELISAs were performed with tetramethylbenzidine substrate. Protein expression and purification Human IL-17RA WT and D262 mutant proteins were generated with the Bac-to-Bac Baculovirus Expression System (Life Technologies) as previously described (27) . High-titer recombinant baculovirus was used to infect Sf9 insect cells at a density of 2 × 10 6 viable cells/ml. The cells were cultured at 28°C and harvested 72 hours after infection. The soluble, secreted, hexahistidine-tagged proteins were purified from the culture medium with a nickel-affinity chromatography column and then with Superdex 200 10/300 GL column (GE Healthcare).
Binding studies by microscale thermophoresis and fluorescence measurement The interactions of WT or mutant IL-17RA proteins with A18 were investigated with a NanoTemper Monolith NT.115 instrument, which was used to measure changes in the fluorescence of labeled IL-17RA that were caused by A18. Purified IL-17RA protein was labeled with the RED fluorescent dye NT-647-NHS (NanoTemper Technologies) according to the manufacturer's protocol. A18 was mixed with the labeled IL-17RA (22 nM) at different concentrations in 50 mM tris-HCl (pH 7.5), 150 mM NaCl, 10 mM MgCl 2 , 0.05% Tween 20, and 2.5% DMSO. The extent of the interaction between the IL-17RA protein (WT or mutant) and IL-17A was determined by microscale thermophoresis (MST). Unlabeled IL-17A was prepared in MST buffer [50 mM tris-HCl (pH 7.5), 150 mM NaCl, 10 mM MgCl 2 , and 0.1 % Pluronic F-127] and mixed with the labeled IL-17RA (22 nM) at different concentrations. The samples were incubated at room temperature for 10 min and loaded into MST premium glass capillary tubes. Data were acquired at room temperature using 20% light-emitting diode power and 20% MST level. At least two independent experiments were performed. Data analysis was performed with MO.Affinity Analysis software (NanoTemper Technologies).
SPR measurement
The extent of binding of A18 to IL-17RA was measured on a Biacore T100 instrument. Purified IL-17RA was immobilized on a CM5 sensor chip with an amine coupling kit (GE Healthcare). Solutions of different concentrations of A18 in PBSPP + buffer [20 mM sodium phosphate, 2.7 mM KCl, 137 mM NaCl, and 0.05% P20 (pH 7.4)] were allowed to flow over the chip. The chip was regenerated with 2 M GnHCl. K d values were determined with BIAevaluation software.
Differential cell counting and histology staining BAL and peritoneal lavage cell counts were determined by cytospin slide preparation after a Diff-Quik Giemsa stain. For histological analysis, mouse lung tissue was fixed in 10% buffered formalin and then subjected to H&E staining.
Peritoneal administration of IL-17A Eight-week-old female WT BALB/cJ mice were subjected to intraperitoneal injection with PBS or with 0.5 mg of IL-17A alone or in the presence of A18 (120 mg per mouse). Six hours later, the peritoneal cavities of the injected mice were lavaged with 5 ml of ice-cold PBS. Peritoneal neutrophils were counted and quantified by differential cell counting.
Intranasal injection of IL-17A and IL-17E Eight-week-old female WT BALB/cJ mice were subjected to intranasal injection with PBS or with 0.5 mg of IL-17A or IL-17E in the presence or absence of A18 (60 mg per mouse) in PBS. BAL and lung tissues were collected at 4 hours (for the IL-17A-treated group) or 24 hours (for the IL-17E-treated group) after injection for BAL cell counting and RT-PCR analysis, respectively.
Intradermal injection of IL-17A
The ears of 8-week-old female WT C57BL/6 were injected intradermally with 20 ml of PBS alone or with PBS containing 0.5 mg of recombinant mouse IL-17A in the presence or absence of A18 (60 mg per mouse). A18 (120 mg per mouse) was also administered (intraperitoneally) daily. Six days after injection, the ears were fixed in 10% formalin and stained with H&E. Epidermal thickness was quantified by ImageJ software.
TPA-induced skin hyperplasia
The dorsal skin of 8-week-old female WT C57BL/6 mice was treated with 12.5 mg of TPA (Sigma-Aldrich, P8139) in 200 ml of acetone in the presence or absence of A18 (60 mg per mouse) on days 1 and 4. A18 (120 mg per mouse) was also administered (intraperitoneally) daily. On day 7, the dorsal skin were fixed in 10% formalin and stained with H&E. Epidermal thickness was quantified by ImageJ software.
Adoptive transfer models for antigen-induced airway inflammation The methods for the T H 17 cell-and T H 2 cell-based adoptive transfer experiments were adapted from published studies (47, 48) . Naïve CD4 + CD44
− T cells were sorted from the spleens and lymph nodes of OT-II TCR transgenic mice. To generate OVA-specific T H 17 cells, we cultured naïve CD4 + T cells with irradiated splenic feeder cells in the presence of OVA 323-339 peptide (5 mg/ml), TGF-b (5 ng/ml), IL-6 (20 ng/ml), IL-23 (10 ng/ml), anti-IL-4 mAb (20 mg/ml), and anti-IFN-g mAb (20 mg/ml). OVA 323-339 -specific T H 2 cells were polarized with IL-4 (20 ng/ml) and anti-IFN-g mAb (20 mg/ml). T H 17 or T H 2 cells were then transferred intravenously into female WT C57BL/6 mice (5 × 10 6 cells per mouse). The mice were challenged (intranasally) with OVA 323-339 (50 mg/ml) 1 day before transfer and three consecutive days after transfer. BAL cell counting and tissue collection were performed 24 hours after the last challenge. For A18 treatment, mice were injected (intraperitoneally) with A18 (120 mg per mouse) on each challenge day.
HFD intervention
Starting at 4 weeks of age, male WT C57BL/6 mice were fed with a CD (10 kcal % fat) or a HFD (60 kcal % fat) for 14 weeks. The HFD + A18 group of mice were injected (intraperitoneally) with A18 (120 mg per mouse) daily for the final 4 weeks before being subjected to AHR measurement. Both the CD (D12450B) and HFD (D12492) were obtained from Research Diets Inc.
Measurement of AHR AHR was measured in mice in response to increasing doses of inhaled methacholine by flexiVent as described previously (49) . Each mouse was aerosolized with methacholine in saline at doses of 0, 25, 50, and 100 mg/ml. Lung resistance was determined with the forced oscillation technique by flexiVent 5.2 software.
HDM-induced asthma
Eight-week-old female WT C57BL/6 mice were sensitized subcutaneously with HDM (100 mg per mouse; Dermatophagoides farina, Greer Laboratories) in complete Freund's adjuvant (CFA) on day 0 and subsequently challenged (intranasally) with HDM (100 mg per mouse) on day 14. AHR measurement, BAL cell counting, and tissue collection were performed 24 hours after the last HDM challenge. The HDM + A18 group of mice were injected (intraperitoneally) with A18 (120 mg per mouse) on days 13 and 14 and were also administered with A18 (60 mg per mouse) (intranasally) 1 hour before challenge.
Adoptive transfer of T H 1 or T H 17 cells to induce EAE MOG 35-55 -specific T H 1 or T H 17 cells were polarized as described previously (12, 13) . To induce T H 1 cell-or T H 17 cell-mediated EAE, we injected (intraperitoneally) 10-week-old female WT C57BL/6J mice with polarized MOG 35-55 -specific T H 1 or T H 17 cells (5 × 10 7 cells per mouse) with or without A18 (60 mg per mouse) after sublethal irradiation (500 rads). A18 (120 mg per mouse) was continuously administered (intraperitoneally) to the treated mice every other day after the transfer of the T H 1 or T H 17 cells. At the peak of disease severity, the mice were sacrificed and perfused with PBS. The spinal cords were fixed in 10% formalin, which was followed by staining with either H&E or Luxol fast blue to evaluate inflammation and demyelination, respectively. The brains were removed and homogenized in ice-cold tissue grinders and filtered through a 100-mm cell strainer, and the cells were collected by centrifugation at 400g for 5 min at 4°C. The cells were resuspended in 30% Percoll and centrifuged onto a 70% Percoll cushion in 15-ml tubes at 800g for 30 min. Those cells at the 30 to 70% interface were collected and subjected to flow cytometric analysis after staining with the appropriate antibodies. CD4 + CD25 + Foxp3 + T reg cells were stained with the Mouse Treg Flow Kit.
and Actb: forward, 5′-GGCTGTATTCCCCTCCATCG-3′ and reverse, 5′-CCAGTTGGTAACAATGCCATGT-3′.
Statistical analysis
A nonparametric Mann-Whitney test (performed with GraphPad Prism software) was used for all comparisons unless otherwise noted in the figure legends. All results are shown as means ± SEM. P < 0.05 was considered statistically significant.
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